Community Support & Engagement Committee

The Community Support & Engagement Committee focuses on fostering a sense of community among CPS members and promoting engagement in activities that support the well-being of both members and the broader community. This committee plays a vital role in creating a positive and supportive environment for psychiatrists to enjoy.


Committee Chair: Manu Suresh Sharma, MD, FAPA

Read more about Dr. Sharma.

 


If you are a member of this committee, click below to access committee resources. Member login is required, and as a reminder, your username is your email address (email associated with your APA membership). If you need to reset your password, click here.

Community Support & Engagement Committee Resources (login required)


Dr. Sharma joined the Institute of Living/Hartford Hospital in 2022.  Before joining the IOL he served as the Unit Chief of the Inpatient Psychosis Unit at Yale New Haven Psychiatric Hospital. His journey in medicine started at Mysore Medical College and Research Institute in India. His passion for psychiatry led him to pursue a Psychiatry Residency at the University of Texas Health Science Center in Houston, where he served as the Chief Resident during his final year of training. Currently, Dr. Sharma holds the position of Assistant Clinical Professor of Psychiatry at the Yale School of Medicine. Moreover, he is also a valued member of the American Psychiatric Association Committee on Innovation. As the Assistant Medical Director for Research and Innovation, Dr. Sharma plays a pivotal role in bridging the gap between ongoing cutting-edge research and clinical practice across the campus. He collaborates closely with the Hartford Healthcare Innovation Office to establish meaningful partnerships with digital health start-up companies. These innovative alliances hold the potential to revolutionize the practice of Psychiatry, enhance the overall patient experience, and elevate the standards of mental health treatment. His personal research interest lies in exploring speech and language samples as biomarkers that can be used to develop clinical decision tools for treating individuals experiencing psychosis.